NCT04516941 — drugset

Summary

There is emerging evidence that patients with SARS-CoV-2 are affected by increased coagulopathy, including in the most advanced forms, a fully blown disseminated intravascular coagulation, leading to multi organ failure (MOF). Post-Morten observations from patients who died because of SARS-CoV-2 infection in Bergamo, Italy and other places have revealed the presence of diffuse venous, arterial and microcirculatorythrombosis, not only restricted to the lung but also involving the kidneys, heart and gut. Thrombin plays a central role in mediating clot forming as well as in mediating inflammation. A direct factor X inhibitor, namely edoxaban can act as prophylactic measure to mitigate the risk of venous and arterial thrombotic complications. Colchicine is an inexpensive (generic drug), orally administered, and a potent anti-inflammatory medication. It might accelerate SARS-CoV-2 clearance. The aim of the CONVINCE study is therefore to assess the safety and efficacy of edoxaban and/or colchicine administration in SARS-CoV-2 infected patients who are managed outside the hospital with respect to the occurrence of fatalities, hospitalisation, major vascular thrombotic events or the SARS-CoV-2 clearance rate under RT PCR.

Timeline

Start: 2021-01-21
Primary completion: 2022-08-31
Completion: 2022-08-31

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Colchicine	Small molecule	0.5 mg	Oral
Comparator	Edoxaban	Small molecule	30 mg	—
Comparator	Edoxaban	Small molecule	60 mg	—

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

Summary

Timeline

Publications

Drugs

Indications